Annual Report

Overview

The report records Group revenue of RMB3,241.6 million in 2025, up from RMB1,710.2 million in 2024, driven by higher sales of telitacicept and disitamab vedotin and the telitacicept licensing transaction. It highlights expanded commercialization of both core products, including new approvals, hospital listings and NRDL renewals. The report also describes the June 2025 Vor Bio licensing agreement, including USD125 million of total consideration and potential milestone payments of up to USD4.105 billion.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2025
Period: Ends 31 December 2025
Publication date: 27 March 2026
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services